- BriaCell Therapeutics (BCTX, Financial) will present four clinical data presentations at the ASCO 2025 Annual Meeting in Chicago.
- The sessions include a Phase III pivotal trial and Phase I/II survival results for breast cancer treatment.
- Presentations scheduled for June 2, 2025, with abstracts available online on May 22, 2025.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) is poised to unveil significant clinical trial data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3 at McCormick Place, Chicago. As a clinical-stage biotechnology firm, BriaCell focuses on developing novel immunotherapies with the goal of transforming cancer care.
Among the presentations are three poster sessions and a publish-only abstract, all dedicated to advanced metastatic breast cancer treatments. Key highlights include:
1. An update on the Phase III pivotal trial of Bria-IMT combined with a checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer, set for June 2, 2025, from 9:00 AM to 12:00 PM CDT.
2. Phase I/II survival results of Bria-IMT with checkpoint inhibitor compared to benchmark trials.
3. A trial-in-progress study regarding Bria-OTS cellular immunotherapy for metastatic recurrent breast cancer.
4. A publish-only abstract examining the impact of HLA Matching on clinical outcomes in Phase 2 trials.
The abstracts will be made public on May 22, 2025, at 5:00 PM ET and subsequently, presentation copies will be accessible through BriaCell's website, allowing investors and the scientific community to engage with the findings.
For more information, please visit the BriaCell Therapeutics website.
